AstraZeneca: Non-alcoholic Fatty Liver Disease trials

The registry lists 19 Non-alcoholic Fatty Liver Disease studies with AstraZeneca as lead sponsor. 0 are open to participants now and 7 have results posted.

Phase 1 10Phase 2 8Phase 3 1No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With FibrosisCompletedNCT05809934Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With FibrosisCompletedNCT05364931Phase 2Results posted
• A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH.CompletedNCT04019561Phase 2Results posted
• A Double-blind Randomized Placebo-controlled Study Comparing Epanova and Fenofibrate on Liver Fat in Overweight Subjects.CompletedNCT02354976Phase 2Results posted
• A Study to Investigate Effects of Omega-3 Carboxylic Acids and Dapagliflozin on Liver Fat Content in Diabetic PatientsCompletedNCT02279407Phase 2Results posted
• Clinical Study In Infants With Rapidly Progressive Lysosomal Acid Lipase DeficiencyTerminatedNCT02193867Phase 2Results posted
• Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase DeficiencyCompletedNCT01371825Phase 2/3Results posted
• A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and OverweightActive, not recruitingNCT06151964Phase 1/2
• Non-alcoholic Steatohepatitis Registry Platform StudyTerminatedNCT06123858
• A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy ParticipantsCompletedNCT05848440Phase 1
• A Thorough QTC Study to Assess the Effect of Cotadutide on Cardiac Repolarization in Healthy ParticipantsTerminatedNCT05668936Phase 1
• Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver DiseaseCompletedNCT05560607Phase 1
• A Randomised, Open-Label Study to Evaluate the Relative and Absolute Bioavailability of Cotadutide in Healthy SubjectsCompletedNCT05294458Phase 1
• Study to Assess the Safety, Tolerability, and Pharmacokinetics (Movement of Drugs Within the Body) of AZD2693 in Healthy ParticipantsCompletedNCT05107336Phase 1
• A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis PatientsCompletedNCT04483947Phase 1
• A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese SubjectsCompletedNCT04142424Phase 1
• AZD4076 in Type 2 Diabetic Subjects With Non-Alcoholic Fatty Liver Disease.CompletedNCT02826525Phase 1
• A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male SubjectsCompletedNCT02612662Phase 1
• A Study to Identify and Characterize LAL-D Patients in High-risk PopulationsTerminatedNCT02345421